Description

Simple

Clinical

Overview

Remikiren is an orally active, high specificity renin inhibitor.

Pharmacology

Indication

For the treatment of hypertension and heart failure

Pharmacodynamic

Remikiren is an orally available renin inhibitor with an established blood pressure-lowering effect in patients with essential hypertension. No data are available on the renal effects of remikiren in humans. In patients with essential hypertension, a single oral dose of remikiren can induce a renal... Read more

Mechanism of action

Several in vivo experiments have shown that remikiren is specific for renin and does not decrease arterial pressure by an unrelated mechanism.

Absorption

Absorbed following oral administration.

Protein binding

83%

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

Information currently not available.

Route of elimination

Information currently not available.

Toxicity

Information currently not available.

Adverse Effects

Contraindications

Information currently not available.

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Remikiren
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
1-benzylimidazole
1-benzylimidazole may decrease the antihypertensive activities of Remikiren.
2,5-Dimethoxy-4-ethylamphetamine
2,5-Dimethoxy-4-ethylamphetamine may decrease the antihypertensive activities of Remikiren.
2,5-Dimethoxy-4-ethylthioamphetamine
2,5-Dimethoxy-4-ethylthioamphetamine may decrease the antihypertensive activities of Remikiren.
4-Bromo-2,5-dimethoxyamphetamine
4-Bromo-2,5-dimethoxyamphetamine may decrease the antihypertensive activities of Remikiren.
4-Methoxyamphetamine
4-Methoxyamphetamine may decrease the antihypertensive activities of Remikiren.
5-methoxy-N,N-dimethyltryptamine
5-methoxy-N,N-dimethyltryptamine may decrease the antihypertensive activities of Remikiren.
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Remikiren.
Abediterol
Abediterol may decrease the antihypertensive activities of Remikiren.
Acebutolol
The therapeutic efficacy of Remikiren can be increased when used in combination with Acebutolol.
Aceclofenac
The therapeutic efficacy of Remikiren can be decreased when used in combination with Aceclofenac.
Acemetacin
The therapeutic efficacy of Remikiren can be decreased when used in combination with Acemetacin.
Acepromazine
Acepromazine may decrease the antihypertensive activities of Remikiren.
Acetylsalicylic acid
The therapeutic efficacy of Remikiren can be decreased when used in combination with Acetylsalicylic acid.
Adrafinil
Adrafinil may decrease the antihypertensive activities of Remikiren.
Alclofenac
The therapeutic efficacy of Remikiren can be decreased when used in combination with Alclofenac.
Aldesleukin
The therapeutic efficacy of Remikiren can be increased when used in combination with Aldesleukin.
Alfentanil
Alfentanil may decrease the antihypertensive activities of Remikiren.
Alfuzosin
Alfuzosin may increase the hypotensive activities of Remikiren.
Aliskiren
The therapeutic efficacy of Remikiren can be increased when used in combination with Aliskiren.
Alminoprofen
The therapeutic efficacy of Remikiren can be decreased when used in combination with Alminoprofen.
2 References
  1. 1 . Clozel JP, Fischli W: Discovery of remikiren as the first orally active renin inhibitor. Arzneimittelforschung. 1993 Feb;43(2A):260-2.PubMed: 8498974
  2. 2 . Richter WF, Whitby BR, Chou RC: Distribution of remikiren, a potent orally active inhibitor of human renin, in laboratory animals. Xenobiotica. 1996 Mar;26(3):243-54.PubMed: 8730917